| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Z-Asp-OH is classified as a protected amino acid derivative and an aspartic acid analogue. It does not have a specific biological receptor target. The Z group provides orthogonal protection for the N-terminus, enabling selective deprotection and peptide bond formation. It serves as a building block in peptide synthesis and the preparation of various bioactive compounds. It is a standard reagent for introducing aspartic acid residues into peptides.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity for Z-Asp-OH is primarily as a peptide synthesis reagent. Amino acid derivatives have been commercially studied as ergogenic supplements, influencing the secretion of anabolic hormones, fuel supply during exercise, and mental performance. Z-Asp-OH itself is not directly biologically active. Its utility is in preparing aspartic acid-containing peptides for subsequent biological evaluation. |
| ln Vivo |
In vivo activity data for Z-Asp-OH as a standalone compound is not applicable. It is a protected amino acid building block used in research and is not intended for direct in vivo administration. Peptides synthesized using this building block may be evaluated in animal models for various biological activities. The Z protecting group is typically removed before any biological testing of the final peptide products.
|
| Enzyme Assay |
In vitro SPPS protocols for Z-Asp-OH involve standard peptide synthesis chemistry. The compound is activated using coupling reagents and coupled to a growing peptide chain. The Z group is removed by catalytic hydrogenolysis (H₂/Pd) or by treatment with HBr in acetic acid. Purity is typically ≥99.0% by titration. Coupling efficiency is monitored by standard methods like HPLC or the Kaiser test.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Z-Asp-OH as it is a synthesis building block. Aspartic acid-containing peptides synthesized using this reagent can be tested in cell culture. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability, proliferation, and specific signaling readouts.
|
| Animal Protocol |
Animal studies with Z-Asp-OH are not conducted directly. Peptides containing aspartic acid residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs. The aspartic acid residue can influence peptide charge and structure.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Z-Asp-OH as a standalone compound is not applicable. The compound has a molecular weight of 267.23 g/mol and is a solid at room temperature. It is soluble in DMSO (100 mg/mL). Storage is recommended as a powder at -20°C for long-term stability. The Z group is removed by hydrogenolysis or acid treatment during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Toxicological data for Z-Asp-OH is limited but it is generally considered to have low acute toxicity. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use. Store as a powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Z-Asp-OH (CAS#: 1152-61-0) is also known as N-Cbz-L-aspartic acid, N-Benzyloxycarbonyl-L-aspartic acid, and ((benzyloxy)carbonyl)-L-aspartic acid. Its molecular formula is C12H13NO6. It is a standard building block for peptide synthesis used to introduce L-aspartic acid residues with orthogonal N-terminal protection. It has no approved therapeutic indications.
|
| Molecular Formula |
C12H13NO6
|
|---|---|
| Molecular Weight |
267.2347
|
| Exact Mass |
267.074
|
| CAS # |
1152-61-0
|
| PubChem CID |
2723942
|
| Appearance |
White to off-white powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
472.8±45.0 °C at 760 mmHg
|
| Melting Point |
117-119 °C(lit.)
|
| Flash Point |
239.7±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
1.72
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
19
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C(=O)O[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
XYXYXSKSTZAEJW-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C12H13NO6/c14-10(15)6-9(11(16)17)13-12(18)19-7-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,18)(H,14,15)(H,16,17)/t9-/m0/s1
|
| Chemical Name |
(2S)-2-(phenylmethoxycarbonylamino)butanedioic acid
|
| Synonyms |
Z-Asp-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~374.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7421 mL | 18.7105 mL | 37.4209 mL | |
| 5 mM | 0.7484 mL | 3.7421 mL | 7.4842 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7421 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
